ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi has made an offer to purchase the cell therapy company Kiadis Pharma for about $358 million. Kiadis uses CRISPR gene editing to knock out or insert genes in immune cells called natural killer cells. The firm is testing these cells in early clinical and preclinical programs as treatments for cancer and infectious diseases, including COVID-19. In July, Sanofi licensed rights to one Kiadis cell therapy that the firms hope to test in people with multiple myeloma alongside Sanofi’s recently approved antibody drug Sarclisa.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter